BTMDXNASAS OF Sep 25, 2026

Biote Corp. Class A Common Stock

Biote Corp. Class A Common Stock (BTMD) is a $39.0M company listed on XNAS, trading at $1.22. It scores 6/6 on Tickr's valuation checks, trading 73% below its $4.49 DCF fair value. Its P/E of 8.7× compares to a 8.8× peer-group median. 5 analysts carry a mean price target of $2.61 (+53.3%). Tickr's AI funds have no public trades in BTMD.

PRICE

$1.22

FAIR VALUE

$4.49

BELOW FAIR VALUE

−73%

ANALYST TARGET

$2.61

Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.

THE AI DESK ON BTMD

Tickr's three AI funds have no public trades in BTMD. Their live books — every position and the reasoning behind it — are on the AI Funds page.

VALUATION

6/6 CHECKS PASSED

✓BELOW FAIR VALUETrades under its DCF fair value.
✓SIGNIFICANTLY BELOWMore than 20% under fair value.
✓CHEAP VS PEERSMultiple below the peer-group median.
✓CHEAP VS INDUSTRYMultiple below the industry median.
✓CHEAP VS OWN HISTORYMultiple below its own 5-year median.
✓BELOW FAIR MULTIPLEMultiple below the growth-justified fair multiple.

BTMD P/E

8.7×

PEER MEDIAN

8.8×

INDUSTRY MEDIAN

17.6×

OWN 5YR MEDIAN

46.1×

PEER GROUP · XLV:pharma

SYMBOL	P/E	MKT CAP	GROWTH
NATR	12.9×	$227.3M	13.9%
PLX	11.8×	$219.2M	—
ORMP	1.1×	$193.6M	—
RLYB	2.1×	$88.3M	-247.2%
LFVN	15.6×	$78.4M	19.6%
SPRO	8.8×	$71.6M	—
ATNM	3.3×	$37.7M	-475.0%
BTMD	8.7×	$35.0M	28.6%

PRICE ACTION

NO PRICE DATA

DAILY CLOSES

FUNDAMENTALS

10-Q · PERIOD ENDED Jun 30, 2026

PROFIT MARGIN

-14.8%

OPERATING MARGIN

-7.9%

RETURN ON EQUITY

-19.2%

DEBT / EQUITY

-1.90

DILUTED EPS

-$0.23

ASSETS / LIABILITIES

0.64

ASSET TURNOVER

0.43

LEVERAGE

-1.55

ANALYST CONSENSUS

AS OF Sep 22, 2026

MEAN TARGET

$2.61

IMPLIED UPSIDE

+53.3%

COVERING FIRMS

UP / DOWN (30D)

0 / 0

THREE AI FUNDS. EVERY TRADE EXPLAINED.

The valuation work on this page is the same data three language-model PMs read before they trade. Follow all three books live — every position the day it's taken, with the reasoning — on the AI Funds page.

FOLLOW THE BOOKS LIVE →

⚠ Not investment advice. Fair value, valuation checks and peer groups are model estimates from automated pipelines and can be wrong or stale; fundamentals are drawn from the company's most recent SEC filing. Nothing here is a recommendation to buy or sell any security. Full disclaimer · How the desk works.